Benztropine Mesylate Injections Recalled Over Glass Particulate Risk

Posted on July 2, 2013

The possible inclusion of small pieces of glass within the product has led to the recall of Benztropine Mesylate Injection in 2 mg/mL single dose vials.  Fresenius Kabi USA announced the recall, which affects four lots of product (030712, 071212, 090512, and 111412).  Although no one has reported experiencing any type of adversity at this point, the company has ceased distribution until it can figure out what led to these glass particulates.  The particulates could lead to thromboembolism, phlebitis, granulomas, and more if injected into a patient’s bloodstream.  The vials should not be injected into a patient and should instead be sent back to the company.  Injuries or illnesses should be reported to MedWatch.

For more about the recall, follow this link.

How Can We Help You?

If you have a legal matter you would like to discuss with an attorney from our firm, please call us at (310) 477-1700 or complete and submit the e-mail form below, and we will get back to you.

  • This field is for validation purposes and should be left unchanged.
  • This field is for validation purposes and should be left unchanged.
*Required Fields